TY - JOUR
T1 - Retaining African networks is urgent for global health
AU - Bhiman, Jinal N.
AU - Serwanga, Jennifer
AU - Ugwu, Chinedu A.
AU - Vigan-Womas, Ines
AU - Quashie, Peter K.
AU - Bhattacharya, Jayanta
AU - Sande, Charles
AU - Bonomo, Adriana
AU - Markey, Fatu Badiane
AU - Awandare, Gordon A.
AU - Garg, Pramod Kumar
AU - Kaleebu, Pontiano
AU - Happi, Christian
AU - Rennergarbe, Ashton
AU - Woods, Colleen
AU - Kirchner, Jacqueline
AU - Aguilar, Anastazia Older
AU - Makar, Karen
AU - Moore, Penny L.
N1 - Publisher Copyright:
© 2025 The Authors
PY - 2025/11
Y1 - 2025/11
N2 - The Global Immunology and Immune Sequencing for Epidemic Response (GIISER) network, established in 2021, exemplifies the power of South–South collaboration in pandemic preparedness and response. Emerging from the COVID-19 crisis, GIISER integrated genomic surveillance, immunology, and capacity building across African, Asian, and South American sites, enabling rapid detection and characterization of SARS-CoV-2 variants. Through technology transfer, standardized protocols, and coordinated training, GIISER informed public health policy, advanced monoclonal antibody discovery, and strengthened local expertise. As COVID-19 research subsides and in the context of profound funding constraints, GIISER's scientific successes highlight the urgent need to sustain and expand regional networks to address current and future infectious disease threats, while championing diversity and scientific leadership in low- and middle-income countries (LMICs).
AB - The Global Immunology and Immune Sequencing for Epidemic Response (GIISER) network, established in 2021, exemplifies the power of South–South collaboration in pandemic preparedness and response. Emerging from the COVID-19 crisis, GIISER integrated genomic surveillance, immunology, and capacity building across African, Asian, and South American sites, enabling rapid detection and characterization of SARS-CoV-2 variants. Through technology transfer, standardized protocols, and coordinated training, GIISER informed public health policy, advanced monoclonal antibody discovery, and strengthened local expertise. As COVID-19 research subsides and in the context of profound funding constraints, GIISER's scientific successes highlight the urgent need to sustain and expand regional networks to address current and future infectious disease threats, while championing diversity and scientific leadership in low- and middle-income countries (LMICs).
UR - https://www.scopus.com/pages/publications/105012552642
U2 - 10.1016/j.tim.2025.07.002
DO - 10.1016/j.tim.2025.07.002
M3 - Short survey
AN - SCOPUS:105012552642
SN - 0966-842X
VL - 33
SP - 1150
EP - 1154
JO - Trends in Microbiology
JF - Trends in Microbiology
IS - 11
ER -